Company intelligence / Profile preview

BioRay Pharmaceutical

Shanghai, Shanghai, Chinabioraypharm.com ↗

Ownership: Private
Employees: ~1400
Development stage: Commercial

Overview

BioRay has six marketed products in China across oncology and autoimmune indications. Its lead novel asset Anruixi® demonstrated non-inferiority to Rituximab in a head-to-head Phase III trial for DLBCL with higher complete response rates. The company is advancing next-generation ADCs such as BR111 targeting ROR1 into clinical trials. Over ten additional candidates are in clinical or IND-enabling stages.

Therapeutic areas: OncologyDermatologyImmunologyGastroenterology
Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)BiosimilarsFusion proteins
Industry: Biotech

Drug pipeline

9 assets

BR2251

8 more assets in the full pipeline.

Request access →

Partnerships

PAG Private EquityZhejiang Hisun Pharmaceutical Co., Ltd.Sun Yat-sen Memorial Hospital

Beyond the preview

Go deeper on BioRay Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioRay Pharmaceutical.

Explore the full profile